Literature DB >> 18242716

Oral administration of type-II collagen suppresses IL-17-associated RANKL expression of CD4+ T cells in collagen-induced arthritis.

Ji-Hyeon Ju1, Mi-La Cho, Joo-Youn Jhun, Min-Jung Park, Hye-Joa Oh, So-Youn Min, Young-Gyu Cho, Seu-Yun Hwang, Seung-Ki Kwok, Soo-Hong Seo, Chong-Hyeon Yoon, Sung-Hwan Park, Ho-Youn Kim.   

Abstract

The receptor activator of nuclear factor kappaB ligand (RANKL) is an osteoclastogenic mediator, which is mainly expressed by stromal cells and osteoblast. However, T cells can also be an important provider for RANKL in special condition such as autoimmune arthritis. We examined the RANKL expression of hyporesponsive CD4+ T cells induced by oral feeding with type II collagen in collagen-induced arthritis (CIA) mice. The potential of RANKL expression in CD4+ T cells was downregulated in tolerance, as compared with CIA. One of possible explanations for this phenomenon is that CII-specific T cell activation was intrinsically impaired in oral tolerance, which caused suppression of RANKL expression of CD4+ T cells. We also investigated the extrinsic role of cytokine in this process. IL-17, well-known pro-inflammatory cytokine was upregulated in CIA and downregulated in tolerance. IL-17 had a potential to stimulate T cells to express RANKL in dose-dependent manner. IL-17-associated RANKL expression of CD4+ T cells was downregulated in oral tolerance, suggesting that the induction of tolerance ameliorates IL-17-induced RANKL expression of T cells in murine CIA. We also discovered that CIA - T cells could enhance osteoclastogenesis but not oral tolerance - T cells. Oral tolerance might be promising therapeutic option in viewpoints of modulating autoreactivity of CII which can induce not only IL-17 production but also RANKL expression in CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18242716     DOI: 10.1016/j.imlet.2007.09.011

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  15 in total

1.  Segregated regulatory CD39+CD4+ T cell function: TGF-β-producing Foxp3- and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis.

Authors:  Irina Kochetkova; Theresa Thornburg; Gayle Callis; David W Pascual
Journal:  J Immunol       Date:  2011-10-03       Impact factor: 5.422

2.  IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10.

Authors:  Irina Kochetkova; Sarah Golden; Kathryn Holderness; Gayle Callis; David W Pascual
Journal:  J Immunol       Date:  2010-05-10       Impact factor: 5.422

Review 3.  Oral tolerance.

Authors:  Howard L Weiner; Andre Pires da Cunha; Francisco Quintana; Henry Wu
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

Review 4.  Oral tolerance.

Authors:  Ana M C Faria; Howard L Weiner
Journal:  Immunol Rev       Date:  2005-08       Impact factor: 12.988

5.  Lipoxin A4-Mediated p38 MAPK Signaling Pathway Protects Mice Against Collagen-Induced Arthritis.

Authors:  Jinyu Li; Qi Sun; Chenying Zheng; Chunxiao Bai; Chuyin Liu; Xueqian Zhao; Peiying Deng; Limin Chai; Yusong Jia
Journal:  Biochem Genet       Date:  2020-11-22       Impact factor: 1.890

6.  Combination of MTX and LEF attenuates inflammatory bone erosion by down-regulation of receptor activator of NF-kB ligand and interleukin-17 in type II collagen-induced arthritis rats.

Authors:  Yao Yao; Cong-zhu Ding; Yun Fang
Journal:  Rheumatol Int       Date:  2013-01-19       Impact factor: 2.631

Review 7.  Breaking old paradigms: Th17 cells in autoimmune arthritis.

Authors:  Ariana Peck; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2009-04-28       Impact factor: 3.969

Review 8.  Immunomicrobial pathogenesis of periodontitis: keystones, pathobionts, and host response.

Authors:  George Hajishengallis
Journal:  Trends Immunol       Date:  2013-10-23       Impact factor: 16.687

9.  Obesity aggravates the joint inflammation in a collagen-induced arthritis model through deviation to Th17 differentiation.

Authors:  Joo-Yeon Jhun; Bo-Young Yoon; Mi-Kyung Park; Hye-Joa Oh; Jae-Kyeong Byun; Seon-Young Lee; Jun-Ki Min; Sung-Hwan Park; Ho-Youn Kim; Mi-La Cho
Journal:  Exp Mol Med       Date:  2012-07-31       Impact factor: 8.718

10.  A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis.

Authors:  Wei Wei; Ling-Ling Zhang; Jian-Hua Xu; Feng Xiao; Chun-De Bao; Li-Qing Ni; Xing-Fu Li; Yu-Qing Wu; Ling-Yun Sun; Rong-Hua Zhang; Bao-Liang Sun; Sheng-Qian Xu; Shang Liu; Wei Zhang; Jie Shen; Hua-Xiang Liu; Ren-Cheng Wang
Journal:  Arthritis Res Ther       Date:  2009-12-01       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.